NCT03233776View on ClinicalTrials.gov

Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

April 2, 2020

Study Completion Date

April 2, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

Anakinra

Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.

Trial Locations (1)

6525 GA

Radboud university medical center, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT03233776 - Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT | Biotech Hunter | Biotech Hunter